Enanta Pharmaceuticals, Inc. Share Price
ENTAEnanta Pharmaceuticals, Inc. Stock Performance
Open $11.63 | Prev. Close $11.71 | Circuit Range N/A |
Day Range $11.26 - $11.70 | Year Range $6.46 - $17.11 | Volume 15,360 |
Average Traded $11.56 |
Enanta Pharmaceuticals, Inc. Share Price Chart
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
11-Jun-26 | $11.63 | $11.58 | +0.00% |
11-Jun-26 | $11.63 | $11.58 | +2.03% |
09-Jun-26 | $11.46 | $11.35 | +2.34% |
08-Jun-26 | $11.20 | $11.09 | -1.51% |
05-Jun-26 | $11.49 | $11.26 | -3.92% |
04-Jun-26 | $11.45 | $11.72 | +4.13% |
03-Jun-26 | $12.00 | $11.26 | -6.44% |